The hepatitis A virus (HAV) generally causes mild to moderate self-limited liver disease. However, some patients may develop relapsing (3-20%) or fulminant hepatitis (0.4-2.3%, fatality rate 60-80%) or hematological complications such as granulocytopenia, 1 thrombocytopenia, 2, 3 aplastic anemia, 4 ,5 pure red cell aplasia, 6 hemolysis, 7 and bone marrow aplasia. 8 HAV has worldwide distribution affecting children and adults, especially those living under poor hygienic and sanitary conditions. In Argentina, the overall prevalence of HAV antibodies (anti-HAV) in children is around 50% (range 30-81%), and infection by HAV accounts for 20% of the liver transplants performed for fulminant hepatitis. 9 Four (18%) of 22 anti-HAV positive patients who underwent liver transplantation were reported to have lost their antibodies 1 year after transplantation. 10 Patients undergoing autologous peripheral stem cell (PSCT) or bone marrow transplantation (BMT) can lose their immunity against several diseases such as polio, 11 mumps, measles, rubella, 12 tetanus, 13 leading to the need for reimmunization after transplantation. There are no published data regarding the persistence or loss of anti-HAV after PSCT or BMT.
We evaluated the persistence of anti-HAV in a nonvaccinated population that underwent autologous and allogeneic PSCT.
Material and methods
Between January 1997 and March 2001, all candidates for PSCT at our institution were tested for total anti-HAV within 2 months prior to transplantation. Seropositive patients were retested for anti-HAV following PSCT for various malignancies.
Detection of total anti-HAV was determined using a qualitative commercially available enzyme immunoassay (HÁ VAB s EIA; Abbott Divisio´n Diagno´stico, Abbott Laboratories Argentina SA, Buenos Aires, Argentina). Results were expressed as positive or negative.
The medical records of all PSCT recipients who were anti-HAV seropositive prior to transplantation were reviewed. Variables evaluated included age, gender, underlying disease, type of PSCT, number of CD34 cells infused, and time of anti-HAV testing following PSCT.
Statistical analysis of dichotomous variables was carried out by the w 2 test (Yates corrected) or Fisher's exact test. Student's test was used to assess differences between groups for two continuous variables. To estimate the multivariable predictive value of several independent covariates, one stepwise multiple logistic regression model was used (or Cox's proportional hazards model); degree of fit of the data to model was estimated by the Hosmer-Lemeshow test, and the percentage of the variance was obtained. Statistical significance was taken as o0.05, for two extremes. The software used was CSS/Statistical, 5.1 (Statsoft Corp., Tulsa, OK, USA).
Results
A total of 136 (68%) of 201 PSCT candidates were seropositive for anti-HAV prior to transplantation. Of these 136 patients, 36 had a repeat test for anti-HAV after PSCT and are the subject of this report. None of these 36 patients had a history of immunization against HAV.
Most patients were recipients of autologous PSCT (86%), and had diagnosis of lymphoma (44%) ( Table 1) . Conditioning regimens included cyclophosphamide-BCNU-VP-16 (CBV) for patients with lymphoma, melphalan for patients with multiple myeloma, and busulfancyclophosphamide (BUCY) or busulfan-melphalan (BU-MEL) for patients with leukemia. Patients with solid tumors included two patients with breast cancer and 1 patient with aplastic anemia. These patients received BU-MEL, CBV, and cyclophosphamide as conditioning regimens.
The testing for persistence of anti-HAV was carried out at a median of 12 months (range 1-51) after PSCT, and the results are shown in Table 2 . In all, 31 (86%) of patients remained anti-HAV positive and five (14%) became negative following PSCT. Loss of anti-HAV was observed at a median of 358 days after transplantation (range 31-844).
The variables age, sex, diagnosis, type of PSCT, time of testing following PSCT, and number CD34 cells infused were studied by univariate and multivariate analysis. None of these variables were predictors of persistence or loss of anti-HAV following PSCT. We evaluated the number of CD34 cells infused because these cells will differentiate into most of the cellular components of the immune system. 14 Two allogeneic PSCT recipients received intravenous immunoglobulin (IVIG) (Endobulin S/D, Baxter Immuno SA, Argentina) for prophylaxis of graft-versus-host disease during the first 60 days of transplantation. In these patients, the testing for anti-HAV was carried out 10 and 25 months after receiving the last dose of IVIG.
Discussion
Our findings show that the seroprevalence of total anti-HAV in nonvaccinated adult candidates for PSCT is 68%, and that the majority of these patients maintain these antibodies at a median of 1 year following PSCT.
To our knowledge this is the first report of seroprevalence of anti-HAV among candidates for PSCT. This seroprevalence is comparable to the one observed in our urban adult population. 15 This study is also the first to report the persistence or loss of anti-HAV following PSCT. Our findings are comparable to those observed among recipients of orthotopic liver transplant (OLT). 10 We found a similar pattern of loss of antibodies and we could not identify any patient characteristic that could predict this loss.
Testing for the detection of anti-HAV may not be reliable among allogeneic PSCT recipients who receive IVIG. In our study, only two patients received IVIG. In these patients, the testing for anti-HAV was done long after they discontinued this treatment. Since the half-life of IVIG is of about 3 weeks, it is highly probable that administration of IVIG did not alter the detection of anti-HAV after PSCT. Table 1 Characteristics of peripheral stem cell transplantation (PSCT) recipients who tested positive for total hepatitis A antibodies (anti-HAV) prior to transplantation a Detection of total anti-HAV was determined using a commercially available enzyme immunoassay (HÁ VABs EIA; Abbott Divisio´n Diagno´stico, Abbott Laboratories Argentina SA, Buenos Aires, Argentina). Results were expressed as positive or negative.
Our study is limited by the small number of patients included. In addition, most of our patients were tested before 1 year post-PSCT, and suggests that more patients (414%) may be antibody negative than if they had been tested strictly at 1 year post-PSCT.
We did not have quantitative detection of anti-HAV available; therefore, there is a possibility that some negative results may actually represent low titers of antibodies (o100 mIU/ml) that did not reach the cutoff for a positive qualitative determination. Even so, considering that the mean geometric titer of HAV antibodies after natural infection is 410 000 mIU/ml, 16 a negative qualitative result indicated a significant decline of the level of HAV antibodies. In fact, the study done in OLT recipients showed that anti-HAV continues to decline beyond 1 year after transplantation. 10 This information, plus the fact that protection from hepatitis A beyond a humoral immunity remains unproven, tells us that some PSCT recipients may become susceptible to hepatitis A years after transplantation.
Our findings have important clinical implications for several reasons: (1) HAV is a widespread infection, highly endemic in developing countries (HAV is responsible for 93% of cases of acute hepatitis in Argentina) 17 but also prevalent in developed countries such as the US (HAV is the most commonly reported vaccine-preventable disease and causes around 100 deaths a year due to liver failure) 18 and Finland. 19, 20 (2) HAV may be associated with relapsing infection (3-20%), or fulminant hepatitis (0.4-2.3%, fatality rate 60-80%), and accounts for 20% of OLT performed for fulminant hepatitis in Argentina; 9 (3) HAV can cause several hematological complications that can affect the course of the underlying malignancy including granulocytopenia, 1 thrombocytopenia, 2,3 aplastic anemia, 4,5 pure red cell aplasia, 6 hemolysis, 7 and bone marrow aplasia; 8 (4) Patients may be exposed to an infected, yet asymptomatic individual (50% of acute infections may remain asymptomatic). 21, 22 Owing to these potential problems, we suggest testing PSCT patients for anti-HAV after PSCT and immunize those who are susceptible to HAV. HAV vaccine is an inactivated-virus vaccine. Although there are no studies regarding immunogenicity of this vaccine among PSCT recipients, it has been shown to be safe and immunogenic in other immunocompromised hosts. [23] [24] [25] [26] [27] In conclusion, 14% of nonvaccinated anti-HAV seropositive patients can lose these antibodies 1 year following PSCT. We recommend immunizing these patients.
